Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q3 2020 · 10-Q
Revenue$666.00K$666.00K+24.7% vs Q3 2019 Net Income-$2.39M-$2.39MN/M vs Q3 2019 EPS Diluted-$0.01-$0.01N/M vs Q3 2019 Gross Profit$365,000+36.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,271,000N/M Margins · derivedGross margin54.8%+4.6 pt vs Q3 2019
Operating margin-286.6%+66.2 pt vs Q3 2019
Net margin-358.9%+368.9 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end